meta|Evidence - COVID-19
click on circles to display study description...
ivermectin (n=200) vs. placebo (n=200)
randomized controlled trial some concerns about risk of bias
Ivermectin
300 µg/kg of body weight per day of oral ivermectin in solution, for 5 days.
Placebo
300 µg/kg of body weight per day of oral placebo for 5 days.
Placebo was a solution with similar organoleptic properties to ivermectin. Bottles of ivermectinand placebo were identical throughout the study period toguarantee double-blinding.
COVID 19 outpatients
Adult subjects over 18 years of age with SARS CoV2 / COVID 19 disease confirmed by antigen detection tests authorized by INVIMA or by RT-PCR in any of the laboratories that report to the Departmental Health Secretary, approved for the diagnosis of COVID-19 by the National Institute of Health. Onset of SARS CoV2 / COVID 19 illness 7 days ago or less, subjects with mild disease, informed consent signature.
Double-blind.
Single site in Cali, Colombia.
ivermectin (n=679) vs. placebo (n=679)
randomized controlled trial low risk of bias
Ivermectin 400 mcg/kg up to 90kg weight every 24 hours for 3 days
placebo
COVID 19 outpatients
double-blind
12 public health clinics in Brazil
adaptive platform trial
ivermectin (n=250) vs. placebo (n=251)
randomized controlled trial low risk of bias
ivermectin
24 to 48 mg (depends on the weight of the patient) at day 1 and day 2
placebo
COVID 19 outpatients
double-blind
1 center, Argentina
ivermectin (n=817) vs. placebo (n=774)
randomized controlled trial low risk of bias
ivermectin 400 mcg/kg daily for 3 days
placebo
COVID 19 outpatients
non-hospitalized adults age >=30 years with confirmed COVID-19, experiencing 2 or more symptoms of acute infection for <=7 days
double-blind
ivermectin (n=410) vs. placebo (n=398)
randomized controlled trial some concerns about risk of bias
ivermectin at a dose of 390 to 470 μg per kilogram per day for 3 days
placebo
COVID 19 outpatients
double-blind
US, 6 centres
2-by-3 factorial design (metformin, ivermectin, and fluvoxamine)
ivermectin (n=602) vs. placebo (n=604)
randomized controlled trial low risk of bias
ivermectin, with a maximum targeted dose of 600 μg/kg for 6 days
placebo
COVID 19 outpatients
double-blind
93 sites in the US
ivermectin (n=12) vs. placebo (n=12)
randomized controlled trial low risk of bias
ivermectin
400 mcg/kg, single dose
placebo
COVID 19 outpatients
double bliind
1 center, Spain
ivermectin (n=110) vs. standard of care (n=144)
cluster randomized trial high risk of bias
ivermectin
ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks
standard of care
COVID 19 outpatients
open label
Argentina
ivermectin (n=32) vs. standard of care (n=30)
randomized controlled trial high risk of bias
ivermectin
200 micrograms/kg single dose
standard of care
included antipyretics, cough suppressants, and capsuledoxycycline (100 mg every 12 hours for seven days)
COVID 19 outpatients
open label
1 center, Bangladesh
ivermectin plus doxycycline (n=60) vs. hydroxychloroquine plus macrolides (n=56)
randomized controlled trial high risk of bias
Ivermectin Doxycycline
Ivermectin 200μgm/kg single dose Doxycycline 100 mg BID for 10days
hydroxychloroquine azithromycine
Hydroxychloroquine 400 mg 1st day then200mg BID for 9days Azithromycin 500 mgdaily for 5Days
COVID 19 outpatients
1 center, Bangladesh
powered by vis.js Network